ACM
HRTX icon

Anfield Capital Management’s Heron Therapeutics HRTX Stock Holding History

Anfield Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Hold
30,000
– – 0.01% 331
2025
Q4 		$39K Hold
30,000
– – 0.01% 204
2025
Q3 		$37.8K Hold
30,000
– – 0.01% 207
2025
Q2 		$62.1K Sell
30,000
-111,185
-79% -$227K 0.02% 147
2025
Q1 		$311K Buy
141,185
+22,209
+19% +$43.1K 0.11% 58
2024
Q4 		$182K Buy
118,976
+6,264
+6% +$10.2K 0.07% 73
2024
Q3 		$224K Buy
+112,712
New +$269K 0.09% 65

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Anfield Capital Management's HRTX Position: Q1 2026 in Review

Anfield Capital Management held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 30,000 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #331.

Anfield Capital Management first reported a position in HRTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $311K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Anfield Capital Management held 30,000 shares of Heron Therapeutics worth $24K as of Q1 2026.
  • Anfield Capital Management left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.01% of Anfield Capital Management's portfolio in Q1 2026, its #331 holding.
  • Anfield Capital Management first reported a position in Heron Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Anfield Capital Management's Heron Therapeutics position peaked at $311K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.